How to Cash In When Firms Merge

These funds let Main Street investors profit from Wall Street’s deals.

Wall Street has long been known for deal-making. But after a brisk first half of this year, the pace and value of deals has slowed considerably. Mergers and acquisitions announced in the third quarter of 2019 totaled $218 billion, down from $449 billion in the second quarter, according to research firm S&P Global Market Intelligence. Despite the slowdown, more than 10,000 deals were announced for the year through September 30, valued by S&P Global at nearly $1.1 trillion

It was hard to ignore Occidental Petroleum Corp.'s dramatic courtship of Anadarko, ending in August in an acquisition that S&P Global valued at $57.2 billion. Other big deals announced this year include Bristol-Myers Squibb's pending acquisition of Celgene, which S&P Global calculates is worth a whopping $95 billion, and United Technologies' proposed merger with Raytheon, valued at $91.1 billion. The prospects are good for more M&A, says S&P. Lower interest rates are keeping acquisition financing costs down, and although a rising stock market can make takeover targets more expensive, it can also boost buying power in cash-and-stock deals.

How to invest. The fastest way to benefit from a hot M&A market is to own stock in a takeover target. Investment firm Fidelity estimates that a target's stock typically increases 30% by the time the deal closes. But trying to predict a purchase before it happens is like trying to find hay in a needlestack.

Instead, consider a merger arbitrage fund. After news of a sale goes public, these funds pick up stock of the company being acquired in hopes that they'll profit on the difference between the current share price and the price when the deal closes—if it closes.

Moving Averages


Getty Images

The odds of a deal falling through are slim, but the risk is real. By the time a proposed merger between Pfizer and Allergan fell apart in April 2016, Allergan's stock price had fallen by nearly 20% from where it stood when the deal was announced and by more than 30% from the proposed takeover price. "The downsides in this industry are steep," says Roy Behren, comanager of Merger Fund (symbol MERFX). "When it comes to fund performance, it's not the deals you are in, it's the deals you avoid," he says.

Behren and comanager Mike Shannon have managed the fund, with more than $3 billion in assets, since 2007 and have a solid track record of picking winning deals. In the past 10 years, the fund has returned an annualized 3.1%—above average for market-neutral funds—with below-average volatility. "People invest with us because they want absolute, stable returns," says Behren. Consider that Merger lost a cumulative 5.0% in the 2007–09 bear market, compared with 55.3% for the broad market. The 2.01% expense ratio seems steep, but it compares favorably with other market-neutral funds.

Merger arbitrage exchange-traded funds follow a similar playbook but typically have lower fees and broader criteria for stock selection—which can increase risk. The IQ Merger Arbitrage ETF (MNA, $32), with just under $1 billion in assets, charges 0.77% in expenses. The fund invests in takeover targets headquartered in developed markets, focusing on firms that have profit margins exceeding a certain threshold and whose shares are highly liquid. The ETF won't hold a stock for more than 360 days, says manager Sal Bruno. MNA has returned 2.8% annualized since it launched in late 2009.

It's possible to profit with the companies doing the acquiring—if you know where to look. Health care equipment firm Danaher (DHR, $144) follows an aggressive growth-through-acquisition strategy, but it keeps sprawl in check by cutting costs and overhauling its acquisitions. "Danaher's strength is targeting a bloated company in a strong industry and whipping it into shape," says Mike Bailey, director of research at FBB Capital Partners. The stock has returned 34% over the past year and 19% annualized over the past 10 years. It currently trades at a price-earnings ratio of 27, compared with 17 for the market overall, so look to buy on dips.

Most Popular

Dying Careers You May Want to Steer Clear Of

Dying Careers You May Want to Steer Clear Of

It’s tough to change, but your job could depend on it. Be flexible in your career goals – and talk with your kids about their own aspirations, because…
September 13, 2021
Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
7 Best Commodity Stocks to Play the Coming Boom

7 Best Commodity Stocks to Play the Coming Boom

These seven commodity stocks are poised to take advantage of a unique confluence of events. Just mind the volatility.
September 8, 2021


These 2 Emotional Biases Could Kill Your Retirement
Investor Psychology

These 2 Emotional Biases Could Kill Your Retirement

Are your emotions sabotaging your retirement plans? Some basic knowledge and careful introspection can go a long way toward avoiding major pitfalls.
September 20, 2021
Investment Strategies for the 4 Stages of the Economic Cycle

Investment Strategies for the 4 Stages of the Economic Cycle

The U.S. economy is cyclical in nature, surging ahead and pulling back in waves over time. Investors’ portfolios need to change with the rise and the …
September 19, 2021
Kiplinger's Weekly Earnings Calendar

Kiplinger's Weekly Earnings Calendar

Check out our earnings calendar for the upcoming week, as well as our previews of the more noteworthy reports.
September 17, 2021
Hot Upcoming IPOs to Watch For in the Rest of 2021
Kiplinger's Investing Outlook

Hot Upcoming IPOs to Watch For in the Rest of 2021

The most exciting initial public offerings (IPOs) expected during the remainder of 2021 range from an Amazon-backed EV play to a food delivery app to …
September 16, 2021